Seroprevalence of pertussis and other vaccine preventable diseases in Norway - project description
Reported pertussis incidence in Norway is the highest in Europe although the vaccination coverage is very high. We will carry out a seroepidemiological study in the Norwegian population to map the immune status against Bordetella pertussis in the population. Immunity against B. pertussis may be due to infection or vaccination, and by comparing immune status with vaccination status, this study can provide knowledge about both the vaccine effect and the occurrence of the pertussis in Norway. Statistical strength calculation shows that we should collect about 263 serum samples in each age group below 18 years and approximately 152 serum samples in each age group above 18 years, giving a total of 3010 samples. The results of the study will be of importance for our vaccine recommendation and for targeted prevention of pertussis. It may also be appropriate to investigate seroprevalence against other vaccine preventable diseases.
See the full project description at Cristin for more information about results, researchers, contact information etc.
Ida Laake, Avdeling for infeksjonsepidemiologi og modellering, Norwegian Institute of Public Health
Didrik Frimann Vestrheim, Avdeling for vaksineforebyggbare sykdommer, Norwegian Institute of Public Health
Gro Tunheim, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Jann Storsæter, Avdeling for vaksineforebyggbare sykdommer, Norwegian Institute of Public Health
Tove Karin Herstad, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Ingeborg Aase S. Aaberge, Smittevern, miljø og helse, Norwegian Institute of Public Health